Der tragbare Defibrillator (WCD) – EHRA-Review

Zusammenfassung

Der Kardioverter-Defibrillator nimmt eine zentrale Rolle in der Prävention des plötzlichen Herztodes ein. Neben identifizierbaren Patientengruppen mit anhaltend erhöhtem Risiko für ein arrhythmogenes Ereignis lassen sich auch diejenigen mit einem nur passager erhöhten Risiko für vital bedrohliche Tachyarrhythmien identifizieren. Hier findet der tragbare Kardioverter-Defibrillator (WCD) seine Anwendung. Neben der Funktionsweise des Systems werden die aktuellen Anwendungsbereiche inklusive der Leitlinienempfehlungen zusammengefasst.

Abstract

The cardioverter-defibrillator plays a crucial role in the prevention of sudden cardiac death (SCD). Apart from patients suffering from persistent SCD risk there are those with an only temporary one. This is where the wearable cardioverter-defibrillator applies. Besides a technology overview current indications and guidelines will be outlined.

Schlüsselwörter

plötzlicher Herztod - tragbarer Cardioverter-Defibrillator - WCD - Primärprävention

Key words

sudden cardiac death - wearable cardioverter defibrillator - WCD - primary prevention

• Literatur

• 1 Epstein AE, DiMarco JP, Ellenbogen KA. et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol 2008; 51: e1-e62
• 2 Priori SG, Blomstrom-Lundqvist C, Mazzanti A. et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Europace 2015; 17: 1601-1687
• 3 Reek S, Burri H, Roberts PR. et al. The wearable cardioverter-defibrillator: current technology and evolving indications. Europace 2016; 19: 335-345
• 4 Al-Khatib SM, Hellkamp A, Curtis J. et al. Non-evidence-based ICD implantations in the United States. JAMA 2011; 305: 43-49
• 5 Hohnloser SH, Kuck KH, Dorian P. et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 2004; 351: 2481-2488
• 6 Steinbeck G, Andresen D, Seidl K. et al. Defibrillator implantation early after myocardial infarction. N Engl J Med 2009; 361: 1427-1436
• 7 Exner DV, Kavanagh KM, Slawnych MP. et al. Noninvasive risk assessment early after a myocardial infarction the REFINE study. J Am Coll Cardiol 2007; 50: 2275-2284
• 8 Solomon SD. Zelenkofske S, McMurray JJ et al. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med 2005; 352: 2581-2588
• 9 VEST Study. Im Internet: https://clinicaltrialsgov/ct2/show/NCT01446965 Stand: 01.09.2015
• 10 Zishiri ET, Williams S, Cronin EM. et al. Early risk of mortality after coronary artery revascularization in patients with left ventricular dysfunction and potential role of the wearable cardioverter defibrillator. Circ Arrhythm Electrophysiol 2013; 6: 117-128
• 11 Kao AC, Krause SW, Handa R. et al. Wearable defibrillator use In heart Failure (WIF) Investigators. Wearable defibrillator use in heart failure (WIF): results of a prospective registry. BMC Cardiovasc Disord 2012; 12: 123
• 12 Feldman AM, Klein H, Tchou P. et al. Use of a wearable defibrillator in terminating tachyarrhythmias in patients at high risk for sudden death: results of the WEARIT/BIROAD. Pacing Clin Electrophysiol 2004; 27: 4-9
• 13 Klein HU, Meltendorf U, Reek S. et al. Bridging a temporary high risk of sudden arrhythmic death. Experience with the wearable cardioverter defibrillator (WCD). Pacing Clin Electrophysiol 2010; 33: 353-367
• 14 Chung MK, Szymkiewicz SJ, Shao M. et al. Aggregate national experience with the wearable cardioverter-defibrillator: event rates, compliance, and survival. J Am Coll Cardiol 2010; 56: 194-203
• 15 Kutyifa V, Moss AJ, Klein H. et al. Use of the wearable cardioverter defibrillator in high-risk cardiac patients: data from the prospective registry of patients using the wearable cardioverter defibrillator (WEARIT-II Registry). Circulation 2015; 132: 1613-1619
• 16 Singh M, Wang NC, Jain S. et al. Utility of the wearable cardioverter-defibrillator in patients with newly diagnosed cardiomyopathy: a decade-long single-center experience. J Am Coll Cardiol 2015; 66: 2607-2613
• 17 Kindermann I, Kindermann M, Kandolf R. et al. Predictors of outcome in patients with suspected myocarditis. Circulation 2008; 118: 639-648
• 18 Brinjikji W, El-Sayed AM, Salka S. In-hospital mortality among patients with takotsubo cardiomyopathy: a study of the National Inpatient Sample 2008 to 2009. Am Heart J 2012; 164: 215-221
• 19 Madias C, Fitzgibbons TP, Alsheikh-Ali AA. et al. Acquired long QT syndrome from stress cardiomyopathy is associated with ventricular arrhythmias and torsades de pointes. Heart Rhythm 2011; 8: 555-561
• 20 Sharkey SW, Windenburg DC, Lesser JR. et al. Natural history and expansive clinical profile of stress (tako-tsubo) cardiomyopathy. J Am Coll Cardiol 2010; 55: 333-341
• 21 Nascimento FO, Krishna RK, Hrachian H. et al. Wearable cardioverter defibrillator in stress cardiomyopathy and cardiac arrest. BMJ Case Rep 2013;
• 22 Elkayam U. Clinical characteristics of peripartum cardiomyopathy in the United States: diagnosis, prognosis, and management. J Am Coll Cardiol 2011; 58: 659-670
• 23 Duncker D, Haghikia A, Konig T. et al. Risk for ventricular fibrillation in peripartum cardiomyopathy with severely reduced left ventricular function-value of the wearable cardioverter/defibrillator. Eur J Heart Fail 2014; 16: 1331-1336
• 24 Hilfiker-Kleiner D, Haghikia A, Nonhoff J. et al. Peripartum cardiomyopathy: current management and future perspectives. Eur Heart J 2015; 36: 1090-1097
• 25 Gronda E, Bourge RC, Costanzo MR. et al. Heart rhythm considerations in heart transplant candidates and considerations for ventricular assist devices: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates–2006. J Heart Lung Transplant 2006; 25: 1043-1056
• 26 Opreanu M, Wan C, Singh V. et al. Wearable cardioverter-defibrillator as a bridge to cardiac transplantation: a national database analysis. J Heart Lung Transplant 2015; 34: 1305-1309
• 27 Foley RN, Gilbertson DT, Murray T. et al. Long interdialytic interval and mortality among patients receiving hemodialysis. N Engl J Med 2011; 365: 1099-1107
• 28 Wan C, Herzog CA, Zareba W. et al. Sudden cardiac arrest in hemodialysis patients with wearable cardioverter defibrillator. Ann Noninvasive Electrocardiol 2014; 19: 247-257
• 29 Ponikowski P, Voors AA, Anker SD. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37: 2129-2200